RxDoctor Payments Data

Robert Stauffer, MD

Cardiovascular Disease · Joplin, MONPI 1265478390

Payments from drug & device makers

$8,055in general payments, 2019–2025

Across 112 payments — averaging $71.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Terumo Medical Corporation$1K
  • Medtronic$670
  • Abbott$519
  • Abiomed$473
  • Novartis$242
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$2,68233%
  • Food & beverage$5,27165%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,055 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$218,194
Medicare patients
1,686
Services billed
4,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$111,773
EntrestoSacubitril/Valsartan37$38,650
XareltoRivaroxaban23$20,807
Metoprolol Succinate197$2,210
Prasugrel Hcl19$2,162
Amiodarone Hcl83$1,686
Isosorbide Mononitrate ErIsosorbide Mononitrate131$1,394
ClopidogrelClopidogrel Bisulfate120$1,076
Ranolazine ErRanolazine12$899
Flecainide Acetate31$896
Atorvastatin Calcium116$710
Losartan Potassium85$699
Potassium Chloride50$658
Carvedilol128$645
Nitroglycerin39$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$111,773131 claims
NovartisEntresto$242$38,65037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →